Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.

about

Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.

Item

http://www.wikidata.org/entity/Q38730533

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Treatment Paradigms for Advanc ...... linical Trial Endpoint Design.

@en

type

Item

label

Treatment Paradigms for Advanc ...... linical Trial Endpoint Design.

@en

prefLabel

Treatment Paradigms for Advanc ...... linical Trial Endpoint Design.

@en

P1476

Treatment Paradigms for Advanc ...... linical Trial Endpoint Design.

@en

P2093

Charu Aggarwal

http://www.w3.org/2001/XMLSchema#string

Hossein Borghaei

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial 4.0 License

P2860

Improved endpoints for cancer immunotherapy trials

BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models

Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.

Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

P304

700-708

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1634/THEONCOLOGIST.2016-0345

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2017-04-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28408617

http://www.w3.org/2001/XMLSchema#string

P921

mechanism of action

non-small-cell lung carcinoma

biomedical investigative technique

P932

5469580

http://www.w3.org/2001/XMLSchema#string